🗞 MAKING HEADLINES Herald Sun Reporter, Owen Leonard, met with Botanix executives while they were in Australia this week and has published a story about the Company’s recent acquisition of Sofpironium Bromide. This novel potential treatment for primary axillary hyperhidrosis, a medical condition that results in excessive underarm sweat, is bringing new hope for sufferers. […]
Author Archive for: haleyc
About Haley Chartres
This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 75 entries.
Entries by Haley Chartres
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the Company’s recent acquisition of Sofpironium Bromide. The deal has been called a “transformational acquisition”. Click here to view the report.
Botanix Pharmaceuticals (ASX: BOT) hosted an investor update webinar following the announcement of its acquisition of Sofpironium Bromide, the first and only novel treatment for primary axillary hyperhidrosis. Present on the call was President and Executive Chairman, Vince Ippolito; Executive Director, Matt Callahan; Chief Medical Adviser, Dr Patricia Walker; and Chief Commercial Officer, Howie McKibbon.
Botanix President and Executive Chairman, Vince Ippolito, is a world-leading dermatology executive. In this video, he explains why today’s announcement of our acquisition of Sofpironium Bromide is such a promising commercial opportunity for Botanix – as the first and only new chemical entity developed for the treatment of primary axillary hyperhidrosis.
Botanix Pharmaceuticals (ASX: BOT) executive chairman Vince Ippolito joins Kerry Stevenson on Small Caps to discuss the company’s acquisition of novel dermatology asset Sofpironium Bromide gel.
Botanix has today announced acquisition of a novel dermatology asset known as Sofpironium Bromide, which has been developed to treat primary axillary hyperhidrosis – a medical condition which results in excessive underarm sweating. Sofpironium Bromide is the first and only new chemical entity developed for primary axillary hyperhidrosis, and this product is primed for market […]
Botanix (ASX:BOT) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 31 March 2022 Key highlights from this period include: Strategic appointments to Botanix’s executive leadership team,including Dr Patty Walker as Chief Medical Officer and Mr Howie McKibbon as Chief Commercial Officer Danny Sharp also joins as […]
Botanix is pleased to announce that the US Food and Drug Administration (FDA) Office of Antimicrobial Products has granted new Qualified Infectious Disease Product (QIDP) status for our antibacterial product, BTX 1801. This QDIP designation applies to the use of BTX 1901 to potentially ‘reduce the risk of Staph. aureus bloodstream infections in colonised patients […]
Botanix Pharmaceuticals (ASX:BOT) is pleased to share news of an upcoming poster presentation at the Professional Society for Health Economics and Outcomes Research Annual Meeting (ISPOR 2022) on 15-18 May 2022. ISPOR is renowned for attracting leaders from the global healthcare and outcome research community for discussion and dissemination of the latest trends in healthcare. […]
Botanix Pharmaceuticals (ASX:BOT) is pleased to announce that data for our clinical stage antimicrobial asset, BTX 1801, will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022) on 23–26 April 2022. Results from our clinical program will form the basis of two abstract presentations. The first abstract, titled ‘The Antimicrobial […]